Effect of 30 mCi radioiodine on multinodular goiter previously treated with recombinant human thyroid-stimulating hormone.

Recombinant human thyroid-stimulating hormone (rhTSH) enhances 131I uptake, permitting a decrease in radiation for the treatment of multinodular goiter (MNG). Our objective was to evaluate the safety and efficacy of a single 0.1-mg dose of rhTSH, followed by 30 mCi 131I, in patients with MNG. Seventeen patients (15 females, 59.0 +/- 13.1 years), who had never been submitted to 131I therapy, received a single 0.1-mg injection of rhTSH followed by 30 mCi 131I on the next day. Mean basal thyroid volume measured by computed tomography was 106.1 +/- 64.4 mL. 131I 24-h uptake, TSH, free-T4, T3, thyroglobulin, anti-thyroid antibodies, and thyroid volume were evaluated at regular intervals of 12 months. Mean 131I 24-h uptake increased from 18.1 +/- 9.7 to 49.6 +/- 13.4% (P < 0.001), a median 2.6-fold increase (1.2 to 9.2). Peak hormonal levels were 10.86 +/- 5.44 mU/L for TSH (a median 15.5-fold increase), 1.80 +/- 0.48 ng/dL for free-T4, 204.61 +/- 58.37 ng/dL for T3, and a median of 557.0 ng/mL for thyroglobulin. The adverse effects observed were hyperthyroidism (17.6%), painful thyroiditis (29.4%) and hypothyroidism (52.9%). Thyroid volume was reduced by 34.3 +/- 14.3% after 6 months (P < 0.001) and by 46.0 +/- 14.6% after 1 year (P < 0.001). Treatment of MNG with a single 0.1-mg dose of rhTSH, followed by a fixed amount of radioactivity of 131I, leads to an efficacious decrease in thyroid volume for the majority of the patients, with a moderate incidence of non-serious and readily treatable adverse effects.

[1]  G. Brent,et al.  Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. , 2006, Endocrine-related cancer.

[2]  L. Hegedüs,et al.  Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial. , 2006, Archives of internal medicine.

[3]  G. Medeiros-Neto,et al.  Prolonged follow‐up of multinodular goitre patients treated with radioiodine preceded or not by human recombinant TSH , 2006, Clinical endocrinology.

[4]  C. A. Goedert,et al.  Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodine. , 2005, The Journal of clinical endocrinology and metabolism.

[5]  M. Knobel,et al.  Human recombinant TSH preceding a therapeutic dose of radioiodine for multinodular goiters has no significant effect in the surge of TSH-receptor and TPO antibodies. , 2005, Thyroid : official journal of the American Thyroid Association.

[6]  L. Hegedüs,et al.  The effects of recombinant human thyrotropin, in normal subjects and patients with goitre , 2004, Clinical endocrinology.

[7]  C. Buchpiguel,et al.  Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres , 2004, Clinical endocrinology.

[8]  A. Pinchera,et al.  Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[9]  L. Hegedüs,et al.  Management of simple nodular goiter: current status and future perspectives. , 2003, Endocrine reviews.

[10]  F. Corstens,et al.  Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. , 2001, The Journal of clinical endocrinology and metabolism.

[11]  E. Roti,et al.  Iodine excess and hyperthyroidism. , 2001, Thyroid : official journal of the American Thyroid Association.

[12]  L. Braverman,et al.  Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. , 2001, The Journal of clinical endocrinology and metabolism.

[13]  W. Wiersinga,et al.  A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. , 2001, The Journal of clinical endocrinology and metabolism.

[14]  B. Bravenboer,et al.  Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter. , 2000, The Journal of clinical endocrinology and metabolism.

[15]  B. Weintraub,et al.  A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. , 1999, The Journal of clinical endocrinology and metabolism.

[16]  L. Hegedüs,et al.  The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. , 1999, The Journal of clinical endocrinology and metabolism.

[17]  Wesche,et al.  Determinants of longterm outcome of radioiodine therapy of sporadic non‐toxic goitre , 1999, Clinical endocrinology.

[18]  J. Gross,et al.  Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses. , 1998, The Journal of clinical endocrinology and metabolism.

[19]  L. W. Allen,et al.  Outpatient management of patients with large multinodular goitres treated with fractionated radioiodine , 1997, European Journal of Nuclear Medicine.

[20]  L. Hegedüs,et al.  Thyrotropin Receptor Antibodies and Graves’ Disease, a Side-Effect of 131I Treatment in Patients with Nontoxic Goiter , 1997 .

[21]  J. Barentsz,et al.  Large, Compressive Goiters Treated with Radioiodine , 1994, Annals of Internal Medicine.

[22]  L. Hegedüs,et al.  Radioiodine treatment of multinodular non-toxic goitre. , 1993, BMJ.

[23]  N. Waugh,et al.  Morbidity in patients on l‐thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH , 1992, Clinical endocrinology.

[24]  W. Wiersinga,et al.  Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre , 1990, The Lancet.

[25]  L. Hegedüs,et al.  Reduction of size of thyroid with radioactive iodine in multinodular non-toxic goitre. , 1988, BMJ.

[26]  T. Fahey.  Low-dose recombinant human thyrotropin-aided radioiodine treatment of large, multinodular goiters in elderly patients , 2007 .

[27]  W. Nieuwlaat.  Recombinant Human Thyrotropin as an Adjuvant to Radioiodine Therapy for Nontoxic, Nodulal Goiter. , 2005 .

[28]  L. Hegedüs,et al.  Recombinant human thyrotropin markedly changes the 131I kinetics during 131I therapy of patients with nodular goiter: an evaluation by a randomized double-blinded trial. , 2005, The Journal of clinical endocrinology and metabolism.

[29]  W. Wiersinga,et al.  Reduction in goiter size by 131I therapy in patients with non-toxic multinodular goiter. , 1995, European journal of endocrinology.

[30]  J. Andrews,et al.  Treatment of non-toxic multinodular goiter with radioactive iodine. , 1988, The American journal of medicine.

[31]  J. Horáček,et al.  Pretreatment with a Single , Low Dose of Recombinant Human Thyrotropin Allows Dose Reduction of Radioiodine Therapy in Patients with Nodular Goiter , 2022 .